Inclusion Criteria:  Age ≥ 18 ≤ 75 Progressive disease on or after anti-PD-1/anti-PD-L1 monotherapy or progressive disease on or after anti PD-1 plus anti-CTLA-4 therapy The patient has histologically confirmed metastatic melanoma HLA-A2 positive At least one measurable parameter according to RECIST version 1.1 guidelines ECOG performance status of 0 or 1 No significant toxicity from previous cancer treatments (CTC ≤ 1) Women of childbearing potential: Negative serum pregnancy test and must use effective contraception. This applies from screening and until 6 months after treatment. Birth control pills, spiral, depot injection with gestagen, subdermal implantation, hormonal vaginal ring and transdermal depot patch are all considered effective contraceptives Men with female partner of childbearing potential must use effective contraception from screening and until 6 months after treatment. Effective contraceptives are as described above for the female partner. In addition, documented vasectomy and sterility or double barrier contraception are considered effective contraceptives Signed statement of consent after receiving oral and written study information Willingness to participate in the planned treatment and follow-up and capable of handling  The patient has met the following haematological and biochemical criteria:  AST and ALT ≤2,5 X ULN or ≤5 X ULN with liver metastases Serum total bilirubin ≤1,5 X ULN or direct bilirubin ≤ ULN for patient with total bilirubin level > 1,5 ULN Serum creatinine ≤1,5 X ULN ANC (Absolute Neutrophil Count) ≥1,000/mcL Platelets ≥ 75,000 /mcL Hemoglobin ≥ 9 g/dL or ≥ 5.6 mmol/L  Exclusion Criteria:  Another malignancy or concurrent malignancy unless disease-free for 3 years Requirement for immunosuppressive doses of systemic corticosteroids (>10 mg/day prednisone or equivalent) or other immunosuppressive drugs within the last 3 weeks prior to screening Prior treatment with adoptive transfer of Tumor Infiltrating T cells (TIL) Grade 3-4 adverse events upon treatment with PD-1 checkpoint inhibitors (only phase B) The patient has CNS metastases and/or carcinomatous meningitis The patient has any condition that will interfere with patient compliance or safety (including but not limited to psychiatric or substance abuse disorders) The patient is pregnant or breastfeeding The patient has an active infection requiring systemic therapy The patient has received a live virus vaccine within 30 days of planned start of therapy Significant medical disorder according to investigator; e.g severe asthma or chronic obstructive lung disease, dysregulated heart disease or dysregulated diabetes mellitus. Concurrent treatment with other experimental drugs Any significant active autoimmune disease Severe allergy or anaphylactic reactions earlier in life Known hypersensitivity to one of the active drugs or one or more of the excipients. Unrelieved lower urinary tract obstruction